Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Hezbollah sees potential win as Israel backs down from disarmament goal - 2Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 3Whale stranded off Germany for days is stuck again
- 4Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- 5How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- Beddings of 2024: Track down Your Ideal Fit for a Tranquil Rest
- Savvy Cleaning: The 6 Robot Vacuums of 2024
- Germany unveils rescue plan for struggling chemical sector
- Architect Frank Gehry has died: See his most iconic buildings
- In vogue Sleepwear Patterns for 2024
- 9 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia
- Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Investigate Something else for Less: Financial plan Travel Objections
- Countdown to Artemis II: What to know about NASA's moon mission
